Registered outcomes14

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

1 to 14 of 14

List	Outcome	Time frame
Primary	Number of Participants with Treatment-emergent Adverse Events	Up to approximately 2.5 years
Primary	Number of Participants with Treatment-related Adverse Events	Up to approximately 2.5 years
Primary	Number of Participants with Clinically Significant Changes in Vital Signs	Up to approximately 2.5 years
Primary	Number of Participants with Clinically Significant Changes in Clinical Laboratory Tests	Up to approximately 2.5 years
Secondary	Percentage of Participants with Prostate-specific Antigen (PSA) < 0.2 ng/mL at 6 Months	6 months
Secondary	Time to PSA Progression	Up to approximately 4.5 years
Secondary	Time to First New Systemic Anticancer Therapy	Up to approximately 4.5 years
Secondary	Time to Radiographic Progression per Prostate Cancer Working Group 3 (PCWG3) Modified Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1	Up to approximately 4.5 years
Secondary	Observed Concentration at the End of a Dose Interval of Darolutamide	Up to approximately 4.5 years
Secondary	Observed Concentration at the End of a Dose Interval of Abiraterone	Up to approximately 4.5 years
Secondary	Maximum Observed Serum Concentration (Cmax) of Xaluritmag	Up to approximately 4.5 years
Secondary	Time to Cmax (Tmax) of Xaluritmag	Up to approximately 4.5 years
Secondary	Area Under the Concentration Time Curve (AUC) of Xaluritmag	Up to approximately 4.5 years
Secondary	Half-life (t1/2) of Xaluritamig	Up to approximately 4.5 years

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT07140900/registered